This study assessed the first-hand experiences of people with epilepsy using wearable devices continuously over a period of time, with the aim of understanding how acceptable and easy they were to use, and whether it is reasonable to expect that people will use them.
New findings published in the New England Journal of Medicine reveal that the three drugs, levetiracetam, fosphenytoin, and valproate, are equally safe and effective in treating patients with refractory status epilepticus.
The FDA approved 11/21/2019 XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults.
Spanish-speaking American patients with psychogenic nonepileptic seizures were significantly more depressed and anxious and reported greater exposure to sexual trauma as compared with persons with epilepsy.
Seizure activity in forebrain induces pronounced autonomic activation and disrupts activity in medullary respiratory centers, resulting in death from either obstructive or central apnea.
The aim of this study was to compare parent-reported Health Related Quality of Life (HRQoL) and behavior of young people before (baseline) and two years after pediatric epilepsy surgery (follow-up).
UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
Pediatric Epilepsy
Despite orphan designations for rare epilepsies having dramatically increased in the past 10 years, the number of approved drugs remains limited and restricted to a handful of epilepsy syndromes.
Pediatric Epilepsy
Children with early onset of febrile seizures and especially those with recurrent febrile seizures may be at heightened risk for poorer verbal and processing speed functioning and hence at risk of acquiring cognitive, executive dysfunctions.
